title: Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis.
abstract: OBJECTIVE
  Evaluate the reduction in migraine-associated symptoms after administration of a single oral dose of almotriptan.
  
  
  METHODS
  This pooled analysis (N=1773) used data from three randomized, placebo-controlled, phase III trials (studies A, B, and C) to determine the incidence of migraine-associated symptoms (defined as nausea, vomiting, photophobia, and phonophobia) 2 hours after a single oral dose of study medication (almotriptan, sumatriptan, or placebo). Outcome data was extracted from studies A and B for placebo and the almotriptan 6.25-mg and 12.5-mg groups, and from study C for placebo, almotriptan 12.5-mg, and sumatriptan 100-mg groups.
  
  
  RESULTS
  The incidence of nausea, photophobia, and phonophobia at 2 hours after dosing with study medication was significantly reduced (all P <.05) with almotriptan 6.25 mg or 12.5 mg compared with placebo. The percentage of patients with vomiting was lower with both doses of almotriptan in studies A and B compared with placebo, although differences were significant only for the 6.25-mg dose in study A (P <.001). For study C, the incidence of nausea, vomiting, photophobia, and phonophobia was similar for almotriptan and sumatriptan and lower than with placebo at 2 hours after dosing. Significant reductions (all P <.05) versus placebo were observed in the incidence of vomiting and phonophobia with almotriptan 12.5 mg, and photophobia and phonophobia with sumatriptan 100 mg.
  
  
  CONCLUSIONS
  Almotriptan provides relief from migraine-associated symptoms of nausea, vomiting, photophobia, and phonophobia, and thus represents an attractive treatment option for a wide spectrum of migraine symptomatology.
authors.affiliation: Primary Care Network, Springfield, MO 65084, USA.
authors.forename: Roger
authors.initials: R
authors.lastname: Cady
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000150:complications* / Q000188:drug therapy*; D009325:Nausea / Q000188:drug therapy / Q000209:etiology; D020795:Photophobia / Q000188:drug therapy / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018170:Sumatriptan / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014363:Tryptamines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014839:Vomiting / Q000188:drug therapy / Q000209:etiology
chemical_list: D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C409045:almotriptan; D018170:Sumatriptan